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Abstract
Background: Substance misuse is a well-recognized co-morbidity to psychosis and has been linked to poor
prognostic outcomes in patients. Researchers have yet to investigate the difference in rates and characteristics
between first-episode Substance Induced Psychosis (SIP) and primary psychosis. We aimed at comparing patients
with SIP to primary psychosis patients with or without substance misuse at baseline.
Methods: Thirty SIP patients, 45 primary psychosis patients with substance misuse (PS) and 66 primary psychosis
patients without substance misuse (PNS) in a well-defined Norwegian catchment area were included from
2007–2011. Assessments included symptom levels (PANSS), diagnostic interviews (SCID), premorbid function scale
(PAS) and global functioning (GAF f/s).
Results: Treated incidence for SIP was found to be 6.5/100 000 persons per year, 9.7/100 000 persons per year for
PS and 24.1/100 000 persons per year for PNS (15-65 yrs). Patients who had substance misuse (PS and SIP) were
more likely to be male. Duration of Untreated Psychosis (DUP) was significantly shorter in the SIP group (5.0 wks.,
p = 0.003) and these had more positive symptoms on the PANSS (p = 0.049). SIP patients also did poorer on early
youth academic levels on the PAS.
Conclusions: Yearly treated incidence of SIP is 6.5/100 000 persons per year in a Norwegian catchment area. SIP
patients have short DUPs, are more likely to be male, have more positive symptoms at baseline and poorer
premorbid academic scores in early adolescence. Follow-up will evaluate stability of diagnosis and characteristics.
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Background
Distinguishing between substance-induced psychosis (SIP)
and primary psychosis is crucial for understanding illness
and providing optimal treatment. Substance use is wide-
spread and causes concern for many reasons, particularly
the psychotogenic properties of many substances [1-3].
Substance misuse is a well-recognized co-morbidity to
schizophrenia, and rates of substance use are significantly
higher in psychiatric patients than in the general popula-
tion [4-7]. Studies comparing substance users to non-
substance users [8-11] in psychosis have shown that
persistent misuse in early course of illness is linked to
higher readmission rates and more severe psychopath-
ology [11-13]. Substance use cessation has been associated
with reduced negative symptoms in first episode patients
[12,14,15], highlighting the need for more research with
regards to accurate diagnosis and treatment.
SIP patients are more likely to be homeless, have anti-
social personality disorder, poor family support, positive
family history of mental illness, more insight, more
trauma as well as forensic history, and more hallucina-
tions [16-18]. Substance misusers are more frequently
male [19,20] compared to non-users in primary psych-
osis. Demonstrated better cognitive performance in sub-
stance abuse groups has been linked to the necessity for
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social skills in obtaining illegal drugs [21], and yet there
is also evidence of poor academic performance [19,22].
Several substances are linked to the development of
psychosis and schizophrenia [23,24] and diagnoses of sub-
stance induced psychosis have been included in ICD-10
[25] and DSM-IV [26]. The relationship between drug use
and schizophrenia is probably complex [27], but meta-
analysis of prospective population-based studies have esti-
mated a doubling of risk of psychosis for cannabis, even
after controlling for confounders such as reverse causation
or intoxication effects [28,29]. In amphetamine users, rates
of psychotic symptoms range from 5.2-100% [2,30,31],
with this variation attributed to differences in sampling,
methodology and extent of use.
Determining the correct diagnosis can be challenging
in early-phase psychosis and is further complicated by
substance misuse. Substance induced psychosis (SIP) is
in DSM-IV defined as a condition in which psychotic
symptoms are caused by psychoactive substances and
resolve within a set time period. In order to fulfil the
diagnosis, SIP must be more severe than expected from
intoxication or abstinence and warrant the need for
healthcare. The ICD-10 SIP diagnosis requires partial
resolution of symptoms within one month and full reso-
lution within six months, whereas the DSM-IV demands
symptom remission within one month.
Diagnostic change over time is common for psychotic
disorders, [3,17,32] ranging from 25-50% in SIP patients,
but distinguishing and studying groups is important as
they demand different treatment approaches and are
often excluded from studies. Dependence or harmful use
of any drug, visual hallucinations and losing contact with
services have been suggested as predicting factors for
SIP patients receiving a diagnosis of primary psychosis
[32,33]. Literature suggests that diagnostic change is partly
due to the evolution of the illness, partly our diagnostic
systems where many by default get psychosis NOS
diagnoses when criteria for other psychotic illnesses are
not fulfilled.
Few studies have examined incidence of SIP, and these
patients are often excluded from studies [24,34]. How-
ever, one study to systematically include SIP extracted
data from the Danish Psychiatric Central Register, focusing
on cannabis and comparing it to schizophrenia spectrum
disorders [3]. The study estimated incidence of cannabis-
induced psychosis in Denmark at 2.7 per 100 000 persons
per year.
To our knowledge, no other study has described the
treated incidence of SIP, including all substances. We
wanted to investigate this in a well-defined catchment
area and explore the differences in baseline characteris-
tics compared with primary psychosis patients with and
without substance misuse aiming for a better under-
standing of characteristics and symptom patterns. Our
working hypothesis was that SIP is rare compared to
other first episode psychosis (FEP) and that SIP patients
have more positive symptoms than primary psychosis
patients [35]. Pre-morbidly, we would expect patients
with substance misuse to have better social function, but
poorer functioning academically [19,22].
Methods
The Early Identification and Treatment of Psychosis
(TIPS II) study [36] is a prospective clinical trial con-
ducted in a Norwegian catchment area, investigating
first-episode psychosis (FEP) through detection teams.
We work actively at recruiting patients through infor-
mation campaigns and visibility at schools, health cen-
tres and doctors’ practices.
TIPS was designed to identify and follow clinically
epidemiologic samples of FEP patients from Rogaland
County, Norway, in the Stavanger University Hospital
catchment area in the south and the Health Fonna Hos-
pital catchment area in the north. The population of 185
337 in the south sector and 66 255 in the north sector
(15–65 years) [37] live mainly in urban and suburban
areas. The general medical system in Norway is national-
ized, as is secondary psychiatric care. All hospital admis-
sions and secondary care out-patient treatment are
referred to the two sector hospitals.
TIPS II [36] (2002-ongoing) is a continuation of the
early detection TIPS I study (1997–2000) [19,38-40]. From
2007 onwards, TIPS entered a new phase, including new
patients, and for the first time also substance induced
psychosis patients, dividing patients into three groups
consisting of SIP patients and primary psychosis patients
with and without substance misuse (PS and PNS respect-
ively). Recruitment for this sub-study continued consecu-
tively from August 2007 through December 2011. We
map out biological, symptomatic, cognitive and demo-
graphic characteristics to assess the risk of developing
schizophrenia spectrum disease in the presence of sub-
stance misuse as well as the effect of substance misuse on
on-going psychotic illnesses. Follow-up is planned at 1, 2
and 5 years.
Inclusion criteria consisted of living in the catchment
area; age 15–65 years; meeting DSM-IV-criteria for
schizophrenia, schizophreniform psychosis, schizoaffec-
tive psychosis, delusional disorder, brief psychosis,
affective disorder with mood incongruent delusions,
substance induced psychosis, or psychosis not otherwise
specified; being actively psychotic as measured by the
Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1987); not previously receiving adequate treat-
ment for psychosis (defined as antipsychotic medication
of 3.5 haloperidol equivalents for 12 weeks or until
symptom remission); no neurological or endocrine dis-
orders related to psychosis; no contraindications to
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antipsychotics; fluency in a Scandinavian language and
IQ over 70.
The study was approved by the Regional Committee
for Medical Research Ethics Health Region West and
written informed consent was obtained from all study
participants. The patients entered the study through the
TIPS low-threshold detection team, via local general
practitioners, through the hospital acute inpatient ward
or outpatient clinics.
The Structured Clinical Interview for the DSM-IV
(SCID) was used for diagnostic purposes in all included
patients [41] and performed by a member of the research
team. The team consisted of clinically experienced and
trained research personnel who performed all evaluations
[42]. SCID diagnoses were made on the basis of patients’
own account, co-lateral information and information from
patients’ files. Strict DSM-IV criteria were applied for diag-
noses. Patients were assessed by a member of the detec-
tion team within one week. If patients scored positive for
abuse of drugs at intake, a longer period (> 4 weeks) of
drug-free observation would be initiated before a diagnos-
tic conclusion was made, where possible. Demographic
data was collected for all study eligible patients. Diagnoses
for non-consenters, that is, patients who did not sign in-
formed consent, were either made through SCID or clin-
ical diagnoses from patients’ files. Symptom levels at
intake were measured by the PANSS [43] and global func-
tioning by the Global Assessment of Functioning Scale
(GAF) [44]. The latter scores were split into symptom
(GAFs) and function scores (GAFf). Duration of untreated
psychosis (DUP) was measured as the time in weeks from
the first positive psychotic symptoms to the start of the
first adequate treatment of psychosis (admission to the
study) [45].
Pre-morbid functioning was measured by the Pre-
morbid Assessment of Functioning Scale (PAS) [46],
which describes four pre-morbid periods in life: Child-
hood (up to 11 years), Early adolescence (12–15 years),
Late adolescence (16–19 years) and Adulthood (19 years
and beyond). There are two pre-morbid dimensions: so-
cial; consisting of PAS items social isolation and peer
relationships and academic; which contains school per-
formance and school adaptation. Each item is scored on a
Likert-type scale of 0–6, where lower numbers indicate
normal, healthy functioning and higher numbers suggest
pathological development.
Social functioning for the year prior to treatment was
measured with the Strauss–Carpenter scale [47]. Raters
were trained by rating pre-prepared case notes and audio/
videotapes before entering the study assessment teams
[36]. Good inter-rater reliability was achieved on major
parameters in the research group previously [36], and re-
cently; in 2012 a new score were obtained for central mea-
sures from 9 randomly selected clinical vignettes from the
baseline data. Reliability of measurements for DUP was
0.8 (ICC), and for diagnostic categories; K = 0.9.
Statistical analyses
Analyses were performed using the SPSS Statistical Pro-
gram Package v 20.0 [48]. Mean values are reported with
standard deviations in parentheses, with median values
applied for skewed variables. DUP was log transformed
prior to analysis with ANOVA. Parametrical tests were
used for normally distributed data whereas non-parametric
tests were applied for all univariate tests to ensure a uni-
form analysis strategy. Categorical variables in 2×2 cross-
tabs were analyzed using Fisher’s exact test. All tests are
two-tailed. Outcome measures were corrected for the
potential effect of gender differences applying ANCOVA
(Analysis of covariance and log linear analysis, both with
gender as a covariate).
Age-specific incidence rates of first-episode psychosis
were calculated in yearly bands and expressed per 100
000 persons per year. The denominators for incidence
calculation rates were based on estimated resident mid-
year population figures for our catchment area, for each
of the years 2007–2011, stratified by age [49].
Results
A total of 345 patients were referred to our service in
from August 2007- December 2011. About half of pa-
tients were hospitalised at time of detection, and this
number remained stable when analysing only included
patients. 114 of these were non-eligible due to reasons
such as living in a different sector, organic psychosis, pre-
vious treatment, congruent affective psychosis or non-
psychotic illnesses. 51 SIP cases were identified and 25 of
these were included in the TIPS II study (percentage re-
fusing inclusion; SIP 43.2%, PS 30.1%, PNS 52.5%), along
with five patients from the North Sector. Patients from
the north sector did not differ from remaining patients on
any parameters (Figure 1).
Treated incidence for the Stavanger University Hos-
pital catchment area was calculated as 6.5/100 000 per-
sons per year for SIP, 9.7/100 000 persons per year for
PS and 24.1/100 000 persons per year for the PNS group
(15-65 yrs) (PNS > SIP and PS; p < .005). As the rate of
detection from the North sector was uncertain, five pa-
tients from this area were included to enlarge sample
size, but excluded from incidence calculations.
Demographic and clinical characteristics are presented
in Table 1. There were significantly more males amongst
the groups of substance misusers (SIP and PS) than in
the PNS group, but no significant differences with regards
to age, number of children or years of education between
groups. The age distribution in the included SIP sample
ranged from 17 through to 53 years, with a mean age of
26.5 (SD 9.7) overall. The PS groups had a greater
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proportion of schizophreniform psychosis, whilst PNS pa-
tients had a higher degree of major depressive disorder.
Both groups had similar rates of schizophrenia.
SIP patients scored higher on the PANSS positive sum
score (p = 0.049). GAF scores did not reveal any differ-
ences. DUP varied greatly between groups with SIP pa-
tients having a median DUP of 5.0 weeks compared to
PNS patients (25.5 weeks) and PS patients (20.0 weeks,
p = 0.003). DUP remained significantly shorter in SIP pa-
tients, even when including patients who did not con-
sent to inclusion (Table 2).
On the PAS, SIP patients did worse than PNS patients
with regards to early adolescent academic levels (p = 0.027)
and tended towards poorer performance on late adolescent
academic levels (p = 0.058) (Table 1).
With respect to diagnostic distribution, Psychosis NOS
represented a large part of PS patients (46.7%) whereas
PNS diagnoses were more evenly distributed (Table 3).
At inclusion SIP patients had less suicide thoughts,
plans or attempts (p = 0.039). There were no differences
between groups with regards to PTSD or significant life
events (p > .05) The Strauss-Carpenter scale revealed that
Figure 1 Overview of patients in the TIPS II study.
Table 1 Premorbid assessment of function (PAS) scores in patients with substance induced psychosis (SIP), psychosis
without substance misuse (PNS) and psychosis with substance misuse (PS)
PAS score SIP PNS PS p
N = 30 N = 66 N = 45
Childhood social level mean (SD) 1.0 (1.3) 1.3 (1.5) 1.0 (1.1) 0.436
Early adolescent social level mean (SD) 1.4 (1.3) 1.6 (1.4) 1.2 (1.3) 0.338
Late adolescent social level mean (SD) 1.7 (1.4) 1.5 (1.4) 1.5 (1.2) 0.831
Adult social level mean (SD) 2.7 (1.4) 1.9 (1.6) 2.2 (1.4) 0.255
Social change adult-child mean (SD) 1.6 (1.5) 0.7 (1.7) 1.1 (1.5) 0.212
Childhood academic level mean (SD) 2.2 (1.2) 1.6 (1.4) 2.2 (1.7) 0.274
Early adolescent academic level mean (SD) 3.1 (1.3) 2.1 (1.4) 2.8 (1.7) 0.027*
Late adolescent academic level mean (SD) 3.0 (1.4) 2.2 (1.4) 2.8 (1.6) 0.058
Academic change mean (SD) 0.8 (1.4) 0.7 (1.7) 0.8 (1.6) 0.917
* p < 0.05.
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the PS group received more social support compared to
the PNS group (p = 0.010). Furthermore, significantly more
SIP patients had admissions lasting less than six months
compared to the PNS group (p = 0.042).
Most of the patients in our sample used cannabis or
amphetamines with SIP patients using significantly more
opiates (Table 4).
Discussion
Our study showed that the treated incidence of SIP and
PS was lower than in the PNS group. There were no dif-
ferences in age, marital status, living arrangements or
GAF scores between groups, but significantly more SIP
patients were male and tended to have less lasting rela-
tionships compared to PNS patients. SIP patients had
Table 2 Baseline characteristics of patients with substance induced psychosis (SIP), psychosis without substance
misuse (PNS) and psychosis with substance misuse (PS) including Positive and negative symptom score (PANSS)
SIP PNS pa PS pb pc
n = 30 n = 66 n = 45
n (%) n (%) n (%)
Male gender 21 (70.0%) 32 (48.5%) 0.049* 32 (71.1%) 0.918
Single marital status 24 (80.0%) 36 (63.2%) 0.142 36 (80.0%) 1.000
Form of living (flat) 21 (70.0%) 53 (80.3%) 0.266 34 (75.6%) 0.594
Married/co-habiting 3 (10.0%) 17 (25.8%) 0.078 6 (13.3%) 0.663
Mean (SD) Mean (SD) Mean (SD)
Age (all detected) 26.6 (8.8) 27.4 (12.3) 25.2 (8.2) 0.281
Included sample 25.2 (8.3) 27.3 (11.0) 26.2 (8.4) 0.382
PANSS positive subscale sum 18.3 (4.7) 15.4 (5.8) 18.0 (5.6) 0.049*
PANSS negative subscale sum 12.7 (4.7) 13.1 (5.4) 13.9 (6.2) 0.582
PANSS general subscale sum 30.8 (5.0) 30.7 (8.6) 31.3 (9.1) 0.9344
PANSS total sum 61.9 (10.7) 59.4 (15.3) 63.5 (17.1) 0.713
GAF symptoms scores 33.0 (7.0) 33.7 (8.8) 31.7 (8.1) 0.579
GAF function scores 39.1 (10.1) 42.7 (12.9) 37.8 (10.8) 0.257
Median (range) Median (range) Median (range)
Duration of untreated psychosis (weeks) 5.0 (0–416) 25.5 (0–1092) 0.005** 20.0 (0–1508) 0.028* 0.003**
*p < 0.05.
**p < 0.01.
abetween SIP and PNS (categorical variables).
bbetween SIP and PS (categorical variables).
cacross all groups (continuous variables).
Table 3 Diagnostic distribution of included sample of patients with substance induced psychosis (SIP), psychosis
without substance misuse (PNS) and psychosis with substance misuse (PS)
DSM-IV diagnosis SIP PNS PS
N = 30 N = 66 N = 45
Alcohol-induced psychotic disorder 291.50 N (%) 1 (3.3%)
Alcohol-induced mood disorder 291.80 N (%) 1 (3.3%)
Substance-induced psychotic disorder, with delusions 292.11 N (%) 14 (46.7%)
Substance-induced psychotic disorder, with hallucinations 292.12 N (%) 14 (46.7%)
Schizophrenia, paranoid type 295.30 N (%) 13 (19.7%) 12 (26.6%)
Schizophreniform disorder 295.40 N (%) 3 (4.5%) 11 (24.2%)
Schizoaffective disorder 295.70 N (%) 8 (12.1%) 2 (4.4%)
Major depressive disorder 296.22, 296.24, 296.34 N (%) 14 (21.2%) 2 (4.4%)
Bipolar disorder 296.40, 296.89 N (%) 4 (6.0%) 2 (4.4%)
Delusional disorder 297.10 N (%) 7 (10.6%) 3 (8.6%)
Brief psychotic disorder 298.80 N (%) 2 (3.0%) 2 (4.4%)
Psychotic disorder NOS 298.90 N (%) 13 (19.7%) (46.7%)
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significantly shorter DUPs than the primary psychosis
groups; 5 vs. 20 and 26 weeks; and more positive psychosis
symptoms. Pre-morbidly, SIP patients had the poorest
scores on early adolescent academic levels, suggesting that
there are problems in this group from adolescence on.
Most of the patients in our sample reported use of
cannabis, amphetamines, or a combination of several sub-
stances. This is consistent with amphetamines and canna-
bis being the two most prevalent illegal substances used in
Norway, with around 15% of people (16–64 years) having
tried cannabis and 1-2% having tried amphetamines [48].
SIP patients however, appeared to have a higher frequency
of opiate use than the PS group, possibly indicating heav-
ier substance use.
The TIPS project involves extensive detection work in
a well-defined catchment area where all patients are ad-
mitted to our hospital. The detection team is based in
the acute admissions ward at the hospital and liaises with
general practitioners, schools and youth centres. Numer-
ous information campaigns have significantly increased
awareness of psychosis in our catchment area [36]. This is
further strengthened by a stable population with low mi-
gration numbers, as one gets a non-selected/”real world
scenario”. Furthermore, the mix between rural and urban
environments is viewed as very representative of the gen-
eral Norwegian population [49]. Still, we consider this a
study of treated incidence rather than true incidence of
first episode psychosis (FEP) as our calculations are based
on help seeking behaviour. With regards to primary FEP it
is reasonable to assume that most patients will require
clinical attention. We do not know whether this is the
case with SIP. Our estimate of treated incidence of 6.5/
100 000 persons per year of SIP is probably a conservative
estimate and requires replication.
Diagnosing psychotic disorders using DSM-IV criteria
may be challenging in a clinical setting when psychosis
co-occurs with substance misuse or with an inadequate
substance-free period. In such cases, the default DSM-
IV diagnosis would be psychosis NOS, due to the lack of
fulfilment of criteria for serious mental illness [44]. This
is a limitation of our study, due to unwillingness to over-
diagnosing primary psychotic disorders in patients pos-
sibly intoxicated or in withdrawal. This is also seen in
other studies [7,33] and may partially explain the high
prevalence of psychosis NOS.
Literature shows that a substantial part of SIP patients
will at some stage be diagnosed with a primary psychotic
disorder, [3,17,32] but with our current diagnostic sys-
tems, we might limit our ability to accurately detect and
separate SIP from primary psychosis illnesses. This further
emphasizes the need for samples such as ours where one
can follow patients prospectively with the aim of finding
characteristics that will allow us to separate the two
groups and determine whether the diagnostic drift is in
fact a drift or merely a case of inaccurate diagnosis. This
article presents baseline data and diagnostic stability will
be addressed in the longitudinal follow-up of our cohort.
Our refusal rate was high in all groups, reflecting the
arduousness of recruiting this patient-group into re-
search as well as into the health care-system, as shown
in other studies involving this group of patients [50,51].
In our sample, around half of SIP patients (53.5%) were
hospitalized at time of inclusion, thus making it easier
for the research team to observe patients substance-free.
The study is strengthened by having demographic data
on all eligible patients. There is some uncertainty in the
diagnoses of non-consenters as these may be based on ini-
tial interviews where status of substance use is unknown
or clinical diagnoses are based on discharge letters.
Many patients are detected, assessed, but then dis-
charge themselves against medical advice, or after the
psychosis has resolved, without leaving any means of
contact, possibly due to lack of insight or being too in-
fluenced by symptoms such as paranoia to be able to
accept offers of treatment. This has also been found by
others [52], and is confirmed in our sample where SIP
Table 4 Distribution of substance use in patients with substance induced psychosis (SIP) and psychosis with substance
use (PS)
PNS PS SIP p
Alcohol N (%) 46 (71.2%) 41 (93.3%) 29 (96.7%) 0.004a*, 0.004b*
Cannabis N (%) 39 (86.7%) 20 (80.0%) p = 0.506
Stimulants N (%) 33 (73.3%) 20 (80.8%) p = 0.533
Cocaine N (%) 11 (24.4%) 8 (32.0%) p = 0.496
Opiates N (%) 9 (20.0%) 11 (44%) p = 0.033*
Sedatives N (%) 14 (31.3%) 8 (32.0%) p = 0.939
Other substances N (%) 15 (33.3%) 11 (44%) p = 0.376
*p < 0.05.
abetween PNS and PS (categorical variables).
bbetween PNS and SIP (categorical variables).
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patients have shorter admissions than the other groups.
However, it should be kept in mind that even short ad-
missions provide opportunities for identifying patients
at risk and planning tailored interventions.
Hallucinations following the intake of drugs are quite
common. Different assessment methods make it difficult
to compare study rates. One study applying the Brief Psy-
chiatric Rating Scale [2], found that 23% had experienced
a symptoms of suspiciousness, unusual thought content
or hallucinations in the past year. DSM-IV criteria only
consider hallucinations due substance intake as psychotic
when they occur in the absence of insight, in contrast to
primary psychosis disorders. Most likely, this is to avoid
over-diagnosing psychosis following drugs that commonly
cause hallucinations. However, several studies suggest that
hallucinations are a key feature of SIP, with SIP patients
being more likely to consider their symptoms psychotic
[16,17]. Intact insight in psychosis has also been reported
as a common feature among most methamphetamine
users with psychotic symptoms [53]. By excluding halluci-
nations in patients with insight for diagnostic purposes,
DSM-IV risks excluding patients with distressing symp-
toms from receiving proper psychiatric treatment as their
symptoms may be ruled clinically insignificant.
Conclusions
It is possible that even our comprehensive detection sys-
tem in a limited catchment area could overlook some
SIP patients due to difficulties in detection and engaging
them in our services. This is further complicated by ob-
stacles in diagnosing and assessing patients. Applying
different test-instruments, diagnostic standards and cut-
off criteria make it difficult to draw definitive conclu-
sions with regards to cause, effect and risk and thus do
not provide us with the solid platform essential to en-
hance our knowledge of these patients.
Our results suggest that that SIP is associated with
more acute onset due to a proximal trigger (substance
misuse) and that more severe symptoms propel patients
into care more rapidly. SIP patients performed poorer aca-
demically than the two other groups in early adolescence,
a finding that is supported by other studies [19,22] and
would, in itself potentially increase risk of substance use.
Our interpretation is, however, limited by not having data
on onset of substance misuse.
Guidelines for assessment and treatments of these pa-
tients as a group are needed as SIP patients may need
different medication, brief medication or no medication
and they may be more susceptible to the adverse effects
of antipsychotic treatment. Future research should focus
on a common methodology to determine incidence rates
and characteristics of SIP patients necessary to inform
best delivery of care, but also to shed light on the trajec-
tory from substance misuse to primary psychosis.
Competing interests
None of the authors declare any competing interests.
This work was supported by the National Research council and Stavanger
University Hospital.
The funding source had no role in the study design, in collection, analyses
and interpretation of data, in writing the report, or in the decision to submit
the paper for publication.
Authors’ contributions
TKL, IJ and JOJ originally designed the study and wrote the protocol. MW
managed the literature searches and analyses as well as statistical analysis
and writing of the manuscript. All authors contributed to and have approved
the final manuscript.
Acknowledgements
Jonny Pettersen, Detection Team, Stavanger University Hospital.
Robert Jørgensen, Detection Team, Stavanger University Hospital.
Kristin Hatløy, Detection Team, Stavanger University Hospital.
Åse Undersrud Bergesen, Detection Team, Stavanger University Hospital.
Kirsten Samuelsen, Detection Team, Stavanger University Hospital.
Author details
1Regional Centre for Clinical Research in Psychosis, TIPS, Stavanger University
Hospital, Armauer Hansensvei, 4014 Stavanger, Norway. 2Faculty of Social
Sciences, Institute of Health, University of Stavanger, Kjell Arholmsgt 41, 4021
Stavanger, Norway. 3Norwegian Centre for Addiction Research, University of
Oslo, P.O box 1039, 0315 Oslo, Norway. 4Norwegian Institute of Public
Health, P.O. box 4404, 0403 Oslo, Norway. 5ORYGEN Research Centre,
University of Melbourne, Locked bag 10, Parkville, Melbourne, VIC 3052,
Australia.
Received: 23 May 2013 Accepted: 18 November 2013
Published: 27 November 2013
References
1. Satel SL, Edell WS: Cocaine-induced paranoia and psychosis proneness.
Am J Psychiatry 1991, 148(12):1708–1711.
2. McKetin R, McLaren J, Lubman DI, Hides L: The prevalence of psychotic
symptoms among metamphetamine users. Addiction 2006, 101:1473–1478.
3. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-jorgensen P: Cannabis-
induced psychosis and subsequent schizophrenia-spectrum disorders:
follow-up study of 535 incident cases. Br J Psychiatry 2005, 187:510–515.
4. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK:
Comorbidity of mental disorders with alcohol and other drug abuse- re-
sults from the epidemiologic catchment area (EDC) study. J Am Med
Assoc 1990, 264(19):2511–2518.
5. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V,
Morgan V, Korten A, Harvey C: Psychotic disorders in urban areas: an
overview of the study on low prevalence disorders. Aust N Z J Psychiatry
2000, 34(2):221–236.
6. Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, Harrison G:
Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry
1999, 174:150–153.
7. Barnett JH, Werners U, Secher SM, Hill K, Brazil R, Masson K, Pernet DE,
Kirkbride JB, Murray GK, Bullmore ET, et al: Substance use in a population-
based clinic sample of people with first-episode psychosis. Br J Psychiatry
2007, 190:515–520.
8. Hambrecht M, Häfner H: Sustance abuse and the onset of schizophrenia.
Biol Psychiatry 1996, 40:1155–1163.
9. Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H: Substance use and the
course of early psychosis: a 2-year follow up of first-admitted subjects.
Eur Psychiatry 2003, 18:133–136.
10. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD:
Substance misuse in first-episode psychosis: 15-month prospective
follow-up study. Br J Psychiatry 2006, 189:229–234.
11. Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G: Impact of severity of
substance use disorder on symptomatic and funcitonal outcome in young
individuals with first-episode psychosis. J Clin Psychiatry 2007, 68(5):767–774.
12. Turkington A, Mulholland CC, Rushe TM, Anderson R, McCaul R, Barrett SL,
Barr RS, Cooper SJ: Impact of persistent substance misuse on 1-year out-
come in first-episode psychosis. Br J Psychiatry 2009, 195:242–248.
Weibell et al. BMC Psychiatry 2013, 13:319 Page 7 of 8
http://www.biomedcentral.com/1471-244X/13/319
13. Addington J, Addington D: Patterns, prdictors and impact of substance
use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007,
115:304–309.
14. González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B,
Haidar MK, Vieta E, Arango C: Cannabis and first-episode psychosis: differ-
ent long-term outcomes depending on continued or discontinued use.
Schizophr Bull 2011, 37(3):631–639.
15. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D,
McGorry PD, Schimmelmann BG: The impact of substance use disorders
on clinical outcome in 643 patients with first-episode psychosis.
Acta Psychiatr Scand 2005, 112(2):141–148.
16. Serper MR, Chou JC-Y, Allen MH, Czobor P, Cancro R: Symptomatic overlap
of cocaine intoxication and acute schizophrenia at emergency presenta-
tion. Schizophr Bull 1999, 25(2):387–394.
17. Caton CLM, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, Schanzer
B: Differences between early-phase primary psychotic disorders with
concurrent substance use and substance-induced psychosis. Arch Gen
Psychiatry 2005, 62:137–145.
18. Fraser S, Hides L, Philips L, Proctor D, Lubman DI: Differentiating first episode
substance induced and primary psychotic disorders with concurrent
substance use in young people. Schizophr Res 2012, 136(1–3):110–115.
19. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO,
Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, et al: Substance abuse in
first-episode non-affective psychosis. Schizophr Res 2006, 88:55–62.
20. Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R,
McCormack J, Lorell BS, Kane J: Are cannabis use disorders associated
with an earlier age at onset of psychosis? A study in first episode schizo-
phrenia. Schizophr Res 2012, 120:101–107.
21. Løberg E-M, Hugdahl K: Cannabis use and cognition in schizophrenia.
Front Human Neurosci 2009, 3:1–8.
22. Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Vaskinn A, Friis S,
Opjordsmoen S, Andreassen OA: The level of illicit drug use is related to
symptoms and premorbid functioning in severe mental illness.
Acta Psychiatr Scand 2008, 118:297–304.
23. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G: Self reported
cannabis use as a risk factor for schizophrenia in Swedis conscripts of
1969: historical cohort study. Br Med J 2002, 325:1199.
24. Arseneault L, Cannon M, Poulton R, Murrey R, Caspi A, Moffit TE: Cannabis
use in adolescence and risk for adult psychosis: longitudinal prospective
study. Br Med J 2002, 325:1212–1213.
25. WHO: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva:
World Health Organisation; 1992.
26. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders. 4th edition. Washington DC: American Psychiatric Association;
2000.
27. Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Løberg
E-M, Medhus S, Tanum L, Franck J: Amphetamine-induced psychosis - a
separate diagnostic entity or primary psychosis triggered in the vulner-
able. BMC Psychiatry 2012, 12. doi: 10.1186/1471-244X-12-221.
28. Arseneault L, Cannon M, Witton J, Murrey RM: Causal association between
cannabis and psychosis: examination of the evidence. Br J Psychiatry
2004, 184:110–117.
29. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M,
Lewis G: Cannabis use and risk of psychotic or affective mental health
outcomes: a systematic review. Lancet 2007, 370:319–238.
30. Smith MJ, Thirtalli J, Abdallah AB, Murray RM, Cottler LB: Prevalence of
psychotic symptoms in substance users: a comparison across
substances. Compr Psychiatry 2009, 50(3):245–250.
31. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A,
Rawson R: Clinical course and outomes of metamphetamine-dependent
adults with psychosis. J Subst Abus Treat 2008, 35(4):445–450.
32. Crebbin K, Mitford E, Paxton R, Turkington D: First-episode drug-induced
psychosis: a medium term follow up study reveals a high risk group.
Soc Psychiatry Psychiatr Epidemiol 2009, 44:710–715.
33. Caton CLM, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, Samet S,
Schnauzer B: Stability of early-phase primary psychotic disorders with
concurrent substance use and substance-induced psychosis. Br J
Psychiatry 2007, 190:105–111.
34. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, Os J:
Prospective cohort study of cannabis use, predisposition for psychosis
and psychotic symptoms in young people. Br Med J 2005, 330:11–14.
35. Harris D, Batki S: Stimulant psychosis: symptom profile and acute clinical
course. Am J Addict 2000, 9(1):28–37.
36. Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, Opjordsmoen
S, Simonsen E, Vaglum P, Larsen TK: The key to reducing duration of
untreated first psychosis: information campaigns. Schizophr Bull 2008,
34(3):466–472.
37. Statistics Norway: Population Data; 2011. http://statbank.ssb.no/statistikkbanken/
Default_FR.asp?PXSid=0&nvl=true&PLanguage=0&tilside=selecttable/MenuSelS.
asp&SubjectCode=02.
38. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S,
Simonsen E, Rund BR, Vaglum P, McGlashan TH: Reducing the duration of
untreated psychosis in first episode psychosis. Arch Gen Psychiatry 2004,
61(2):143–150.
39. Larsen TK, Johannessen JO, McGlashan TH, Friis S, Guldberg C, Haahr U,
Horneland M, Melle I, Opjordsmoen S, Simonsen E, et al: Reducing duration
fo untreated first psychosis: changes in patient characteristics at
presentation. Am J Psychiatr 2001, 158(11):1917–1919.
40. Johannessen JO, Larsen TK, Joa I, Melle I, Friis S, Opjordsmoen S, Lund BR,
Simonsen E, Vaglum P, McGlashan T: Pathways to care for first-episode
psychosis in an early detection healthcare sector. Part of the Scandi-
navian TIPS study. Br J Psychiatry 2005, 187:24–28.
41. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clincial Interview for
DSM-IV Axis I Disorders-Patient Edition (SCID I/P, Version 2.0). New York: New
York State Pscyhiatric Institute, Biometrics Research Department; 1995.
42. Friis S, Larsen TK, Melle I, Al E: Methodological pitfalls in early detection
studies - the NAPE lecture 2002. Acta Psychiatr Scand 2003, 107:3–9.
43. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull 1987, 13:261–276.
44. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders (Dsm-Iv). 4th edition. Washington DC: American Psychiatric
Association; 1994.
45. Larsen TK, McGlashan TH, Moe LC: First-episode schizophrenia: I Early
course parameters. Schizophrenia Bull 1996, 22(2):241–256.
46. Cannon-Spoor HE, Potkin SG, Wyatt RJ: Measurement of premorbid
adjustment in chronic schizophrenia. Schizophr Bull 1982, 8:470–484.
47. Strauss JS, Carpenter WT: The prediction of outcome in schizophrenia II
Relationships between predictor and outcome variables: a report from
the WHO pilot study of schizophrenia. Arch Gen Psychiatry 1974, 31:37–42.
48. EMCDDA: 2010 Annual Report on the State of the Drugs Problem in Europe.
Lisbon: European monitoring centre for drugs and drug addiction; 2010.
49. Johannessen J, McGlashan T, Larsen T, Horneland M, Joa I, Mardal S, Kvebæk
R, Friis S, Melle I, Opjordsmoen S, et al: Early detection strategies for
untreated first-episode psychosis. Schizophr Res 2001, 51:39–46.
50. Tarrier N, Khan S, Cater J, Picken A: The subjective consequences of
suffering a first episode psychosis: trauma and suicide behaviour.
Soc Psychiatry Psychiatr Epidemiol 2007, 42:29–35.
51. Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shockley N, Jenner L,
Clair A: A brief motivational intervention for substance misuse in recent-
onset psychosis. Drug Alcohol Rev 2004, 23:151–155.
52. Mordal J, Holm B, Gossop M, Romøren M, Mørland J, Bramness JG:
Psychoactive substance use among patients admitted to an acute
psychiatric ward: laboratory findings and associations with clinical
characteristics. Nord J Psychiatry 2011, 65:208–215.
53. Matsumoto T, Kamijo A, Miyakawa Y, Endo K, Yabana T, Kishimoto H,
Okudaira K, Iseki E, Sakai T, Kosaka K: Metamphetamine in Japan: the
consequences of metamphetamine abuse as a funciton of route of
administration. Addiction 2002, 97:809–817.
doi:10.1186/1471-244X-13-319
Cite this article as: Weibell et al.: Treated incidence and baseline
characteristics of substance induced psychosis in a Norwegian
catchment area. BMC Psychiatry 2013 13:319.
Weibell et al. BMC Psychiatry 2013, 13:319 Page 8 of 8
http://www.biomedcentral.com/1471-244X/13/319
